Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TYMP | P19971 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | IDE | P14735 | 1/20 | 0.35 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8376599 | 0.83 | KDM4E (0.55) | KDM4EALDH1A1TYMPNPC1JAK2 | |
| SCHEMBL14423060 | 0.79 | TYMP (0.47) | KDM4EALDH1A1TYMPNPC1SMN1; SMN2 | |
| SCHEMBL9592776 | 0.77 | TYMP (0.46) | KDM4EALDH1A1TYMPNPC1SMN1; SMN2 | |
| SCHEMBL1227729 | 0.77 | KDM4E (0.46) | KDM4EALDH1A1TYMPNPC1SMN1; SMN2 | |
| SCHEMBL4975707 | 0.76 | TYMP (0.62) | KDM4EALDH1A1TYMPMEN1KMT2A | |
| SCHEMBL27905864 | 0.74 | ALDH1A1 (0.41) | KDM4EALDH1A1TYMPNPC1SMN1; SMN2 | |
| SCHEMBL648709 | 0.74 | TYMP (0.67) | KDM4EALDH1A1TYMPSMN1; SMN2MEN1 | |
| SCHEMBL1227187 | 0.72 | MAPT (0.45) | KDM4EALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL8150090 | 0.70 | JAK2 (0.53) | JAK2DHODH | |
| SCHEMBL17504395 | 0.69 | TYMP (0.39) | KDM4EALDH1A1TYMPNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240131167-A1 | EGFR Degraders and Associated Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-04-25 | — | — | US | claimed |
| EP-4330251-A1 | EGFR DEGRADERS AND ASSOCIATED METHODS OF USE | BeiGene Switzerland GmbH (CH) | 2024-03-06 | — | — | EP | claimed |
| WO-2022227032-A1 | EGFR DEGRADERS AND ASSOCIATED METHODS OF USE | BEIGENE (BEIJING) CO., LTD. (CN) | 2022-11-03 | — | — | WO | claimed |
| WO-2022228556-A1 | EGFR DEGRADERS AND ASSOCIATED METHODS OF USE | BEIGENE, LTD. (KY) | 2022-11-03 | — | — | WO | claimed |
| US-20120065430-A1 | Application of Metal Amidoborane and Their Derivatives in Reduction Reaction | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2012-03-15 | — | — | US | claimed |
| US-20100074861-A1 | COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-03-25 | — | — | US | claimed |
| EP-2129218-A1 | COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| WO-2008101240-A1 | COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| US-20070048637-A1 | Arylamine polymer and organic thin film transistor | RICOH COMPANY LIMITED (JP) | 2007-03-01 | — | — | US | claimed |
| US-6369237-B1 | ENZYME INHIBITORS OF DNA GLYCOLASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-04-09 | — | — | US | claimed |
| WO-1998039334-A9 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | — | 1999-02-18 | — | — | WO | claimed |
| WO-1998039334-A1 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-09-11 | — | — | WO | claimed |
| US-5118800-A | Oligonucleotides possessing a primary amino group in the terminal nucleotide | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1992-06-02 | — | — | US | claimed |
| US-4623477-A | LIQUID CRYSTALS | CHISSO CORPORATION (JP) | 1986-11-18 | — | — | US | claimed |
| EP-4747245-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137692-A1 | METHODS AND COMPOSITIONS FOR TREATING AND MANAGING ALZHEIMER'S DISEASE | PHARMATROPHIX INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026101751-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACERS FOR THE COMPLEMENT C3A RECEPTOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-0181728-A2 | Light-sensitive silver halide photographic material | KONICA CORPORATION (JP) | 1986-05-21 | — | — | EP | disclosed |
| EP-0164944-A1 | Cephalosporin derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-12-18 | — | — | EP | disclosed |
| US-4094928-A | Carbonylaldiminomethanephosphonates | MONSANTO COMPANY (US) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074861-A1 | COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | PAICS, ABCB4, ALPP | KDM4E 4351/4885ALDH1A1 2421/4885TYMP 58/4885 |
| US-20260137692-A1 | METHODS AND COMPOSITIONS FOR TREATING AND MANAGING ALZHEIMER'S DISEASE | MAPT, PSEN1, PSEN2 | KDM4E 4119/4885ALDH1A1 4625/4885TYMP 1113/4885 |
| US-20240131167-A1 | EGFR Degraders and Associated Methods of Use | EGFR, ERBB2, ERBB3 | KDM4E 927/4885ALDH1A1 3084/4885TYMP 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.